Peptide Library / Immune & Resilience
Thymosin Alpha-1
Also known as: Tα1 (marketed internationally as Zadaxin)
The immune-modulation peptide — an approved drug in 30+ countries that trains the immune system's response rather than suppressing or overstimulating it.
| Typical research dose | 1.5–1.6 mg |
|---|---|
| Frequency | 2× weekly |
| Route | Subcutaneous injection |
| Cycle length | 4–12 weeks depending on goal |
Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.
What it is
Thymosin Alpha-1 is a fragment of a hormone your thymus produces to educate T-cells — the immune system's targeting officers. It's a real pharmaceutical: approved in more than 30 countries (as Zadaxin) for chronic hepatitis B and as an immune adjuvant, though never FDA-approved in the US. That international clinical history gives it one of the strongest human safety records on this site.
What the research looks at
- Immune modulation — the defining trait: it balances immune response — boosting weak responses (infections, post-illness) and calming overactive ones (inflammatory states) rather than pushing one direction.
- Infection outcomes — trials across hepatitis, sepsis, and severe respiratory infection; used clinically in several countries during COVID.
- Vaccine response — approved adjuvant use in some countries for flu vaccines in the elderly.
- Oncology support — studied alongside chemotherapy for immune preservation.
How protocols are commonly structured
The clinical template: 1.6 mg subcutaneous twice weekly — research protocols mirror it, running 4–12 weeks for general immune-resilience interest, longer in clinical settings. It appears in "recovery and resilience" protocols alongside NAD+ and glutathione, and its calm safety record is why.
Reconstitution & storage
Lyophilized powder; bacteriostatic-water reconstitution (calculator), refrigerate after mixing.
Research protocols, not a prescription — talk to a physician before touching anything.